Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

TAÇYILDIZ, NURDAN; Tanyildiz, HİKMET; Dincaslan, Handan; Yavuz, Gulsan; ÜNAL, EMEL; ÖZKAN, ELGİN; SOYDAL, ÇİĞDEM; KÜÇÜK, NURİYE; YILDIZ, YUSUF

doi:10.5812/ijp.4008

Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

TAÇYILDIZ N., Tanyildiz H. G., Dincaslan H. U., Yavuz G., ÜNAL E., ÖZKAN E., ...Daha Fazla

IRANIAN JOURNAL OF PEDIATRICS, cilt.26, sa.2, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 2
Basım Tarihi: 2016
Doi Numarası: 10.5812/ijp.4008
Dergi Adı: IRANIAN JOURNAL OF PEDIATRICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Bone Tumors, Sorafenib, Anti-VEGF, PET, REFRACTORY SOLID TUMORS, PHASE-I TRIAL, ONCOLOGY GROUP, MURAMYL TRIPEPTIDE, PEDIATRIC-PATIENTS, EWING SARCOMA, F-18-FDG PET, OSTEOSARCOMA, DIFFERENTIATION, TEMOZOLOMIDE
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed.